Cases of type 1 diabetes are projected to rise by approximately one-third globally by 2050, with experts pointing to environmental factors as the likely drivers of this increase. In the United States alone, the number of individuals living with the condition is expected to grow from nearly 1.5 million to over 2 million by 2049.
This surge is not attributed to lifestyle factors like obesity, lack of exercise, or poor diet, which are typically associated with type 2 diabetes. Instead, type 1 diabetes is an autoimmune condition where the body produces little or no insulin, a hormone essential for converting sugars into energy. Researchers are investigating a combination of environmental triggers, including viral infections in childhood, air pollution, and exposure to certain chemicals, which they believe interact with genetic susceptibility.
"This increase is happening too quickly to be explained by changes in our genes alone," said Dr. Rosiered Brownson-Smith, an expert from King's College London. "Instead, researchers think that changes in our environment and early-life exposures may be interacting with genetic susceptibility."
While the exact cause remains unknown, potential triggers being explored include viral infections, alterations in the gut microbiome, reduced early-life exposure to microbes, and air pollution. Scientists emphasize that it is unlikely a single factor is responsible, but rather a combination of elements affecting genetically predisposed individuals.
Globally, the number of new type 1 diabetes cases per year is predicted to increase by 14%, from around 530,000 to over 605,000 annually. These projections, developed using a global modeling tool, also consider improvements in diabetes care that allow individuals to live longer with the condition. The international research team, led by experts at the University Hospital of Southern Denmark, noted that increased survival rates contribute to the growing number of people living with type 1 diabetes.
Improvements in insulin therapy, blood glucose monitoring, and specialist diabetes care have significantly enhanced outcomes for patients. While historically people with type 1 diabetes lived 15 to 20 years less than their peers, recent studies suggest this gap has narrowed to about 11 years, indicating substantial gains in longevity.
Despite these advances, the increasing prevalence of the disease places a growing demand on healthcare services. Policymakers are urged to ensure that the rising number of patients have access to necessary lifelong care, including insulin, monitoring equipment, and specialist support. The NHS, for example, is advised to plan for a long-term increase in patients requiring continuous diabetes management.
Symptoms of type 1 diabetes typically manifest rapidly, including severe thirst, frequent urination, and unexplained weight loss. Other signs can include fatigue, blurred vision, and slow wound healing. Treatment involves regular insulin administration, either through injections or an insulin pump, alongside consistent medical check-ups.
Globally, an estimated 450 million people with diabetes remain untreated, a figure that has more than tripled since 1990. In the UK, routine screening for type 1 diabetes is not standard on the NHS, with diagnoses often occurring incidentally or through family history, though experts note that most diagnosed individuals lack a close family history, further supporting the role of environmental factors.